More than 50 randomized trials have documented the efficacy and safety of aspirin as an
antiplatelet agent and a cardiovascular drug. However, the optimal dose for preventing
coronary and cerebral thrombosis has long been a cause of debate. For patients with
ischaemic heart disease the range recommended for the prevention of a secondary event,
based on strong clinical evidence, is 75–160 mg aspirin/day. For patients with
cerebrovascular disease, recommendations range from 30–1300 mg/day. If these patients …